RET and non-small cell lung carcinoma: In the presented case, the disease progression under Pembrolizumab occurred nearly after the European regulatory approval of selpercatinib as the preferred therapeutic option for patients with advanced/metastatic NSCLC positive for RET rearrangement mutations, after first-line chemotherapy [8,15].